FDA
FDA approves Imfinzi with presurgical-only Padcev for bladder cancer

Clinical takeaway: Consider neoadjuvant Imfinzi plus Padcev, followed by adjuvant Imfinzi alone after radical cystectomy, for adults with muscle-invasive bladder cancer (MIBC) who are ineligible for or decline cisplatin-based chemotherapy. This adds a new perioperative option for a population in which radical cystectomy has been the standard approach.
On November 13, 2026, FDA approved Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin-ejfv) as neoadjuvant treatment, followed by Imfinzi alone as adjuvant treatment after radical cystectomy, for adults with MIBC who are ineligible for or decline cisplatin-based chemotherapy. Patients receive three cycles of both drugs before cystectomy, followed by up to nine cycles of Imfinzi alone. Up to half of patients with MIBC are ineligible for cisplatin because of impaired renal function or other comorbidities, and radical cystectomy alone has historically been the standard treatment for these patients.
The approval adds an alternative to perioperative Keytruda (pembrolizumab) plus Padcev, which includes Padcev both before and after surgery. The Imfinzi regimen limits Padcev to treatment before surgery, but the regimens have not been compared directly to determine differences in efficacy or tolerability.
In the phase 3 VOLGA trial, which enrolled 695 patients across three treatment groups, the newly approved regimen improved event-free survival (EFS) and overall survival (OS) compared with radical cystectomy with or without approved adjuvant therapy. It reduced the risk of recurrence, progression, failure to undergo radical cystectomy, or death by 49%, and median EFS had not been reached versus 12.1 months in the comparator group. An estimated 64% of patients remained alive and event-free at 2 years with the regimen, compared with 45% in the comparator group.
The regimen also reduced the risk of death by 42%, and median OS had not been reached in either group at the time of analysis. Estimated 2-year OS was 78% with the regimen and 69% in the comparator group.
Grade 3 or 4 adverse events from any cause occurred in 64% of patients receiving the regimen versus 44% in the comparator group. Common adverse reactions included elevated liver enzymes, decreased hemoglobin, rash, fatigue, and peripheral neuropathy; Imfinzi labeling also carries warnings for immune-mediated adverse reactions.
“Based on this, the VOLGA regimen has the potential to become a new standard of care in this curative-intent setting,” said Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center and a member of the VOLGA steering committee, in the company’s announcement.
Sources: FDA. (2026 Nov 13). FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer; AstraZeneca. (2026 Nov 13). Perioperative Imfinzi approved in the US in novel regimen with neoadjuvant enfortumab vedotin for patients with muscle-invasive bladder cancer